MoneyWorks4Me

Shilpa Medicare gets USFDA’s approval for Varenicline Tablets

09 Apr 2025 Evaluate

ShilpaMedicare has received approval from U.S Food and Drug Administration (USFDA)for Varenicline Tablets, 0.5 and 1 mg. The total US market for this product isaround $203 million.

Thecompany’s product has been approved as a generic version to the innovator -Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism). VareniclineTablets are indicated for smoking cessation; it helps people to quit smoking.

ShilpaMedicare produces and exports consistently high-quality Active PharmaceuticalIngredients Fine Chemicals, intermediates, herbal products and specialitychemical products using sophisticated technology, meticulously followinginternational specifications.

Shilpa Medicare Share Price

821.90 14.50 (1.80%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: